Glucagon vs GLP-1
Head-to-head comparison of Glucagon (Glucagon) and GLP-1 (Glucagon-like peptide-1 (7-36 amide)) — benefits, dosing, side effects, research data, and where to buy.
| Property | Glucagon | GLP-1 |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Glucagon | Glucagon-like peptide-1 (7-36 amide) |
| Molecular Weight | 3482.75 | 3297 Da |
| Half-Life | 5-10 min | 1-2 minutes |
| Amino Acids | 29 | 30 |
| Typical Dose | 1 mg IM/SC for severe hypoglycemia or 3 mg intranasal | Research-only: 0.1-1.0 pmol/kg/min |
| Route | IM|SC|IN|IV | Intravenous/Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 93 | 1200 |
| Research Status | Approved | Pre-clinical |
Glucagon Benefits
- ✓rapid hypoglycemia reversal
- ✓raises plasma glucose
- ✓useful in emergency rescue
GLP-1 Benefits
- ✓beta-cell protection
- ✓improved insulin secretion
- ✓slower gastric emptying
- ✓lower postprandial glucose
Glucagon Dosing
1 mg IM/SC|3 mg intranasal
GLP-1 Dosing
0.1-1.0 pmol/kg/min IV infusion in research|0.5-10 nM in vitro|continuous delivery in animal studies
Glucagon Side Effects
- ⚠nausea
- ⚠vomiting
GLP-1 Side Effects
- ⚠nausea at pharmacologic exposure
- ⚠tachyphylaxis with continuous exposure
- ⚠headache
Research Overview
Glucagon
Clinical and emergency medicine use is well established for severe hypoglycemia, with newer stable formulations improving ease of administration.
GLP-1
Native GLP-1 has a very short half-life because of rapid DPP-4 cleavage, so it is mainly used as a mechanistic research peptide. Across animal and cellular studies it reduces beta-cell apoptosis, improves insulin gene expression, and enhances islet resilience.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.